整理 | GLP1减重宝典内容团队在全球减重市场的竞逐中,除了礼来,诺和诺德无疑是绕不开的重要玩家。凭借旗下明星产品司美格鲁肽在减肥适应症上的爆发式增长,加之社交媒体的“带货效应”,这家丹麦制药巨头市值一路飙升。早在2023年9月,诺和诺德便以4184亿美元的市值登顶欧洲上市公司之首。然而,这家百年药企近来的日子却并不好过。一连串临床试验失利和管线受挫,使其发展步履蹒跚。资本市场对此反应迅速:仅...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.